Reuters logo
BRIEF-Altimmune reports Q3 loss per share $2.05
November 9, 2017 / 9:35 PM / 14 days ago

BRIEF-Altimmune reports Q3 loss per share $2.05

Nov 9 (Reuters) - Altimmune Inc

* Altimmune announces third quarter 2017 financial results and provides corporate update

* Q3 loss per share $2.05

* Q3 preliminary loss per share $0.34 excluding items

* Altimmune Inc qtrly revenue and grants and contracts were $4.6 million versus $0.9 million​

* Altimmune Inc - ‍at september 30, 2017, company had cash and cash equivalents of approximately $17.1 million​

* Altimmune Inc - ‍initiated a phase 2 clinical trial with nasovax vaccine with initial data expected in q1 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below